<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM23416-LXV-W0-KVG"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 S1122 IS: Prioritizing Medical Countermeasures for National Security Act of 2023</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2023-03-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>118th CONGRESS</congress><session>1st Session</session><legis-num>S. 1122</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20230330">March 30, 2023</action-date><action-desc><sponsor name-id="S376">Ms. Ernst</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To improve the program to provide for priority review of human drug applications to encourage treatment for agents that present national security threats.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Prioritizing Medical Countermeasures for National Security Act of 2023</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" id="idded8115aeaf34b65a94082d6ce1c613a" section-type="subsequent-section"><enum>2.</enum><header display-inline="yes-display-inline">Extension and expansion of medical countermeasure priority review voucher program</header><subsection id="idc009e98b0a3448939a3934f8181be0fd"><enum>(a)</enum><header>Definition of medical countermeasure application</header><text>Subsection (a)(4) of section 565A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4a">21 U.S.C. 360bbb–4a</external-xref>) is amended— </text><paragraph commented="no" display-inline="no-display-inline" id="id26092b0faacd48cdb575efddd05acabe"><enum>(1)</enum><text display-inline="yes-display-inline">in the paragraph heading, by striking <quote><header-in-text style="OLC" level="section">Material threat medical</header-in-text></quote> and inserting <quote><header-in-text style="OLC" level="section">Medical</header-in-text></quote>;</text></paragraph><paragraph id="ide868e4bb03e641d99f94c699f8923271"><enum>(2)</enum><text>in the matter preceding subparagraph (A), by striking <quote>material threat</quote>; and</text></paragraph><paragraph id="id710b6d6c15cc4c7b8e83bd2ffe73fb08"><enum>(3)</enum><text>by amending subparagraph (A) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id139caebf0e954b7fb4afc1e6a506ce75"><subparagraph id="iddd75365e12944c2785c22f0522615b53"><enum>(A)</enum><text>is a human drug application for a drug that is—</text><clause id="idaa44310ccab24b599583f178ddd757e3"><enum>(i)</enum><text>labeled for an indication to prevent or treat a disease or condition specifically caused by a chemical, biological, radiological, or nuclear agent; and</text></clause><clause id="idf4b83146c8c64e95bd183eac9f7c3c71"><enum>(ii)</enum><text>part of a class or category of drug on the list described in subsection (b) at the time of approval of the application.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="ide5c1b9aac6ea4f20b04a711fe2b430aa"><enum>(b)</enum><header>List of medical countermeasures for national security threats</header><text>Section 565A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4a">21 U.S.C. 360bbb–4a</external-xref>) is amended— </text><paragraph commented="no" display-inline="no-display-inline" id="idaa4f20e561c54e9b8c2ebf31dd8c9d44"><enum>(1)</enum><text display-inline="yes-display-inline">by redesignating subsections (b) through (g) as subsections (c) through (g) and (i), respectively; and</text></paragraph><paragraph id="id2966a76908dc4d87baf593afdbeda1f6"><enum>(2)</enum><text>by inserting after subsection (a), the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id14bb597696a146168a1d640397f120aa"><subsection id="idd10366b0ec1f4a9a8d5611d015e6c2d0"><enum>(b)</enum><header>List of medical countermeasures for national security threats</header><paragraph commented="no" display-inline="no-display-inline" id="idf2a697c99e084c098745e166da1e6859"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, acting through the Assistant Secretary of Preparedness and Response, in consultation with the Public Health Emergency Medical Enterprise established under section 2801 of the Public Health Service Act, including the Secretary of Defense, shall establish and maintain a list of potentially eligible classes and categories of drugs that are identified as necessary to prevent or treat the diseases and conditions specifically caused by a chemical, biological, radiological, or nuclear agent that—</text><subparagraph id="idb456c51dc0f744e2b9090e552b88e4bd"><enum>(A)</enum><text>has the potential to lead to a public health emergency with significant potential to affect national security; or</text></subparagraph><subparagraph id="id8b0f3cc83d804d91af5d6a5b5a55b79b"><enum>(B)</enum><text>may present a specific threat to the Armed Forces.</text></subparagraph></paragraph><paragraph id="id6ed379b0d1f74751b926a6962d15df24"><enum>(2)</enum><header>Factors</header><text>In establishing and revising the list under paragraph (1), the Secretary may consider—</text><subparagraph id="id2c850fd6bccb4ed3859578d1b6d1bd11"><enum>(A)</enum><text>whether an eligible class or category of drugs that is identified is—</text><clause commented="no" display-inline="no-display-inline" id="id2506839523204ccda2f5eb94eaf86e48"><enum>(i)</enum><text display-inline="yes-display-inline">needed to protect the public health, using the same standard that applies with respect to determinations of material threats under section 319F–2(c)(2)(B)(ii) of the Public Health Service Act; and </text></clause><clause commented="no" display-inline="no-display-inline" id="id0e820365d0ad4a0c8160682ae690ae9b"><enum>(ii)</enum><text display-inline="yes-display-inline">determined to be a priority (consistent with sections 302(2) and 304(a) of the Homeland Security Act of 2002);</text></clause></subparagraph><subparagraph id="id3efc460c3f014a4db41ca77cfa635cce"><enum>(B)</enum><text>for any class or category of drugs under consideration to address specific threats to the Armed Forces, information provided by the Secretary of Defense to help evaluate whether a priority review voucher is necessary and beneficial to incentivize product development for the Department of Defense use and fielding;</text></subparagraph><subparagraph id="id46575bbee2c44bb2b95a302ba3b2fabb"><enum>(C)</enum><text>whether the class or category of drug requires incentivization in the form a priority review voucher based upon economic factors, such as whether there is a sufficient market to support the development of the potential medical countermeasures and the maturity of the medical countermeasure pipeline; </text></subparagraph><subparagraph id="idc18d062a0205456397340c53837f9f34"><enum>(D)</enum><text>the potential effect of an addition of a class or category of drug on the potential sale value of priority review vouchers; and</text></subparagraph><subparagraph id="id649fc216c4b9436fb5e5b6d5ff3efba8"><enum>(E)</enum><text>such other factors as the Secretary determines appropriate.</text></subparagraph></paragraph><paragraph id="id09d67627275a426786f6c777c9b3900e"><enum>(3)</enum><header>Duties</header><text>The Secretary, acting through the Assistant Secretary of Preparedness and Response, shall—</text><subparagraph id="id37ee77028f224ddfaebb7ed1f46f4898"><enum>(A)</enum><text>in coordination with the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Program, disclose to interested priority review applicants the list developed under paragraph (1);</text></subparagraph><subparagraph id="ide1bdd8c0e7d34d618dc42ea2395f5a3a"><enum>(B)</enum><text>periodically review the list developed under paragraph (1) for continued necessity and appropriateness, and add, amend, or remove any classes or categories of drugs if no longer necessary or appropriate; and</text></subparagraph><subparagraph id="id162655fdd8bf4025a5cadc565d54b5fb"><enum>(C)</enum><text>maintain a publicly available archive of the list over time.</text></subparagraph></paragraph><paragraph id="id6f669cf00283438ab4d68cf856721801"><enum>(4)</enum><header>Transition period</header><text>Before the date of the initial publication of the list developed under paragraph (1), the most recent priority list developed under this section before the date of enactment of the <short-title>Prioritizing Medical Countermeasures for National Security Act of 2023</short-title> shall remain in effect.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="idcf934a8bc0794552b33d64adc47ea17f"><enum>(c)</enum><header>GAO report</header><text>Section 565A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4a">21 U.S.C. 360bbb–4a</external-xref>) is amended by inserting after subsection (g), as redesignated by subsection (b)(1), the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id2f86cc50b8a845d1b17f7909ff5217e1"><subsection id="idffe86e3ee2154b4186926df41fcbc459"><enum>(h)</enum><header>GAO report</header><paragraph id="idb272fa91f895421ab471db837f1633c4"><enum>(1)</enum><header>In general</header><text>Not later than September 30, 2027, the Comptroller General of the United States shall transmit to Congress a report on the effectiveness of this section in encouraging the development of the medical countermeasures needed to protect and prepare for emerging threats to public health and national security.</text></paragraph><paragraph id="id14258d218e9a4fe69972abad966d917a"><enum>(2)</enum><header>Contents</header><text>The report shall include—</text><subparagraph id="idc89be64eaada446f9c55f6c5b7b4b455"><enum>(A)</enum><text>input from the Secretary of Defense and the Secretary of Health and Human Services; and</text></subparagraph><subparagraph id="idfee5de053740429aab341ee06813674f"><enum>(B)</enum><text>recommendations of the Comptroller General of the United States, if any, on necessary modifications to this section.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="ida05d20caa68648258a3b734b9cd814c4"><enum>(d)</enum><header>Sunset</header><text>Subsection (i) of such section, as redesignated by subsection (b)(1) of this section, is amended— </text><paragraph commented="no" display-inline="no-display-inline" id="id022a63391d4a46aa83ed5be9ea7e5fcc"><enum>(1)</enum><text display-inline="yes-display-inline">by striking <quote>subsection (b)</quote> and inserting <quote>subsection (c)</quote>; and </text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idb1106cba0ed845b8915a2cc87c5ea43f"><enum>(2)</enum><text display-inline="yes-display-inline">by striking <quote>October 1, 2023</quote> and inserting <quote>October 1, 2029</quote>.</text></paragraph></subsection><subsection id="idd1ce4c7a7aff475e9af42463d7828f47"><enum>(e)</enum><header>Conforming amendments To remove references to material threats</header><text>Section 565A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4a">21 U.S.C. 360bbb–4a</external-xref>) is amended by striking <quote>material threat</quote> each place it appears in—</text><paragraph commented="no" display-inline="no-display-inline" id="id4d294b08f2804971ac50b182a7970e08"><enum>(1)</enum><text display-inline="yes-display-inline">subsection (a)(3);</text></paragraph><paragraph id="id2cfcd0c8870a446fa0d5d539ecca4c78"><enum>(2)</enum><text>paragraphs (1) and (2) of subsection (c), as redesignated by subsection (b)(1); and</text></paragraph><paragraph id="id2e82f77520384b86a060e26d9c5eb9e1"><enum>(3)</enum><text>subsection (f), as so redesignated. </text></paragraph></subsection></section></legis-body></bill> 

